

Vitros Brahms PCT, Ortho Sera clearances

March 11, 2020—[Ortho Clinical Diagnostics](#) announced its Ortho Sera antigen blood phenotyping for patients in need of transfusions has been cleared to run on the Ortho Vision platform in the United States and Canada. Ortho Sera helps to test for more than 99 percent of commonly tested blood group antigens, with results generated in about 20 minutes.

“Ortho Clinical Diagnostics is proud to offer our laboratory partners solutions that help them quickly test donor blood for the most-needed phenotypes and confidently provide it to patients in need of transfusion,” Bob Stowers, head of Ortho’s transfusion medicine product portfolio, said in a press statement. “With the ability to analyze the most commonly tested antigens on a single Ortho Vision system and results in under 25 minutes, lab teams are better equipped to help clinicians focus on what matters most—treating their patients.”

The 13 Ortho Sera reagents available are Anti-D (DVI), Anti-D (IAT), Anti-Fya, Anti-Fyb, Anti-Jka, Anti-Jkb, Anti-K, Anti-Lea, Anti-Leb, Anti-N, Anti-P1, Anti-S, and Anti-s.

The company also announced that its Vitros Brahms procalcitonin assay received FDA 510(k) clearance. The assay, designed to help clinicians identify sepsis and other severe bacterial infections, has a sample size of 30 µL and a calibration interval of 56 days. It will be available on the Vitros 3600 immunodiagnostic system, Vitros 5600 and Vitros XT 7600 integrated systems, and Vitros ECi/ECiQ systems.